Targeted Inhibition of CHD1L by OTI-611 Reprograms Chemotherapy and Targeted Therapy-Induced Cell Cycle Arrest and Suppresses Proliferation to Produce Synergistic Antitumor Effects in Breast and Colorectal Cancer
The second and third most frequently diagnosed cancers worldwide are breast (2.3 million new cases) and colorectal (1.9 million new cases), respectively. Although advances in cancer therapies and early detection have improved the overall survival of patients, patients still develop resistance or can...
Saved in:
| Main Authors: | Hector Esquer, Qiong Zhou, Daniel V. LaBarbera |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-02-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/14/5/318 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CHD1L in cancer and beyond: structure, oncogenic functions, and therapeutic potential
by: Sophia Clune, et al.
Published: (2025-05-01) -
Interference with CHD1L inhibits the malignant progression and enhances cisplatin sensitivity of ovarian cancer cells by binding PLK1
by: Kun Qiao, et al.
Published: (2025-02-01) -
A review on the relationship between the distal 1q21.1 microdeletion and schizophrenia
by: Xinpeng Guo, et al.
Published: (2025-07-01) -
Circadian activity and sleep architecture in autism spectrum disorder mouse model with Chd8 mutation
by: Jiahui Yu, et al.
Published: (2025-08-01) -
PD-1/PD-L1 and coronary heart disease: a mendelian randomization study
by: Liangjia Zeng, et al.
Published: (2024-10-01)